Is NCT03432884 results overdue?

Yes — results are overdue. Primary completion was 2018-04-16; the FDAAA-801 reporting deadline (2019-04-16) passed 2669 days ago and no results are posted on ClinicalTrials.gov.

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

NCT ID	NCT03432884 ↗
Sponsor	BeiGene (INDUSTRY)
Phase	PHASE1
Status	COMPLETED
Primary completion	2018-04-16 (ACTUAL)
Reporting deadline	2019-04-16 (completion + 365d)
Days overdue	2669
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `9ecf73c3d68110c5…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03432884. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.